Zepbound Weight Loss: Labels, Trials and User Reports
Zepbound weight loss: tirzepatide for chronic weight management, how it compares with Wegovy, and what anonymous users report. Not medical advice.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
Zepbound is tirzepatide approved for chronic weight management (and related labels in some regions). Trial programmes reported substantial average weight loss versus placebo in eligible adults; individual results vary and side effects are common. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
What the trials showed
Averages; individual results vary widely. Last reviewed October 15, 2026.
| Trial | Who | Result |
|---|---|---|
| SURMOUNT-1 (72 weeks) | Adults with obesity, no diabetes | About 15%, 19.5% and 21% average loss at the three doses vs about 3% on placebo |
| SURMOUNT-4 (withdrawal) | People who lost weight, then switched to placebo | Regained about 14% of body weight over a year; those who stayed on lost about 5.5% more |
| SURMOUNT-5 (head-to-head) | Zepbound vs Wegovy | 20.2% vs 13.7% |
| SURMOUNT-OSA | Obesity with sleep apnoea | Fewer breathing interruptions; led to a sleep-apnoea indication |
Versus Wegovy and Mounjaro
Zepbound vs Wegovy compares tirzepatide vs semaglutide weight brands. Mounjaro weight loss covers the diabetes-facing tirzepatide brand. Side effects: Zepbound side effects.
What anonymous users describe
#743 lost thirty pounds in a year on Zepbound and decided to be open about it. #384 says most of their loss came after switching from semaglutide to tirzepatide. Regain is the common complaint after stopping (#200). See food noise for how writers describe appetite.
What users report
See the tirzepatide side-effects report and food noise for how writers describe appetite and food thoughts.
Related topics
data reports:
related peptides:
community guides:
More confessions from the archive
Community Q&A
- How fast does Zepbound work?
- In SURMOUNT-1 weight fell steadily for most of the 72 weeks; early months are slower while the dose is increased.
- Do you regain weight after stopping Zepbound?
- In SURMOUNT-4, people switched to placebo regained about 14% of body weight over a year on average.
- How much weight can you lose on Zepbound?
- Trial averages depend on dose arm and population. This page does not predict individual results. Read labels and primary publications with a clinician.
- Zepbound vs Wegovy for weight loss?
- Different active ingredients (tirzepatide vs semaglutide). See Zepbound vs Wegovy. This page does not rank them.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Sources
- SURMOUNT-1 — Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022
- SURMOUNT-4 — Aronne et al., Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024
- SURMOUNT-5 — Aronne et al., Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med 2025
- SURMOUNT-OSA — Malhotra et al., Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024
- Zepbound (tirzepatide) prescribing information — DailyMed (NLM)
- Mounjaro (tirzepatide) prescribing information — DailyMed (NLM)
- Wegovy (semaglutide) prescribing information — DailyMed (NLM)
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.